Should You Buy AstraZeneca plc Instead Of Hikma Pharmaceuticals Plc, BTG plc And GW Pharmaceuticals plc?

Is there better opportunity to make a profit with AstraZeneca plc (LON: AZN) or sector peers Hikma Pharmaceuticals Plc (LON: HIK), BTG plc (LON: BTG) and GW Pharmaceuticals plc (LON: GWP)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2015 has been a rather mixed year thus far for the pharmaceutical sector. That’s because, while the likes of AstraZeneca (LSE: AZN) (NYSE: AZN.US) and BTG (LSE: BTG) have seen their share prices fall by 1.5% and 1% respectively, superb gains have been on offer elsewhere in the sector. For example, Hikma (LSE: HIK) and GW (LSE: GW) have seen their share prices soar by 27% and 26% since the turn of the year.

Looking ahead, though, which of the four is the best buy for longer-term investors?

Valuations

Clearly, pharmaceutical stocks tend to trade at a premium to the wider index, so comparing them directly to the FTSE 100, for example, is unlikely to lead to a conclusion that they offer good value for money. Of course, they tend to trade on premium valuations because of their appealing mix of defensive characteristics and strong growth potential, so even though AstraZeneca has a price to earnings (P/E) ratio of 16.3 (which is higher than the FTSE 100’s P/E ratio of around 16), it still seems to offer good relative value for money.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

That’s because Hikma, BTG and GW have P/E ratios of 26.2, 37.7 and, in the case, of GW, its status as a loss-making company means it does not have a positive P/E ratio. As such, AstraZeneca is certainly the cheapest of the four stocks but, as mentioned, future growth potential can be significant in the pharmaceutical sector.

Growth Prospects

There is a clear split when it comes to the growth forecasts of the four companies over the next couple of years. That’s because, while AstraZeneca’s bottom line is expected to decline in the low-single digits before resuming growth in 2017, and GW’s losses are due to widen in 2015 and 2016, BTG and Hikma have relatively bright futures.

For example, Hikma’s bottom line is forecast to grow by 6% this year and by 15% next year, which puts it on a relatively appealing price to earnings growth (PEG) ratio of 1.6. However, BTG seems to have much greater appeal despite its higher P/E ratio, with it set to post earnings growth of 27% and 53% over the next two years, which puts it on a PEG ratio of just 0.5.

Looking Ahead

Although AstraZeneca is going through a challenging period, with its loss of patents continuing to impact on its bottom line, it still offers excellent value for money relative to its sector peers. Certainly, BTG has considerable appeal, with its stunning prospects meaning that it appears to offer growth at a very reasonable price and could be worth buying at the present time.

Furthermore, Hikma also has great potential to continue its run thus far in 2015, although GW’s forecast increase in losses could cause its share price to come under pressure in the medium term, with investors having other strong options within the pharmaceuticals space available to them.

However, while there is opportunity elsewhere, AstraZeneca still seems to be the pick of the four companies due to its long-term potential and appealing valuation. And, for long term, patient investors, it could deliver stunning share price growth as its acquisition spree is all set to revitalise its top and bottom lines.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Up 33%! Here’s why I’m not buying more Lloyds shares this month

Lloyds shares are on a tear in 2025, up almost a third since the year began. But Mark Hartley remains…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

£3,000 in savings? Here’s how it could be used to start investing and earning a monthly passive income

Christopher Ruane outlines how someone could start investing today with a spare £3K to try and build passive income streams…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Tesco shares go ex-dividend on 15 May. Time to consider buying them?

Harvey Jones admires Tesco shares because they combine solid share price growth with a decent level of dividend income. The…

Read more »

Senior couple are walking their dog through a public park in Autumn.
Investing Articles

Is today’s market turmoil a brilliant opportunity to get a high second income from dividends?

Falling share prices drive up yields in a boost for those after a second income from dividends. Harvey Jones looks…

Read more »

piggy bank, searching with binoculars
Investing Articles

Outlook: in just 12 months the BP share price could turn £10,000 into…

Forecasters seem pretty optimistic about prospects for the BP share price, suggesting it could be in for a major rally.…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Down 28%, is Nvidia stock a bargain – or a value trap?

Nvidia stock has crashed this year -- but it's still a star performer over the long term! So, is this…

Read more »

Investing Articles

£10k invested in Barclays shares at the start of 2025 is now worth…

Harvey Jones says Barclays shares were unlikely to continue 2024's blistering run, given all the uncertainty out there. Yet long-term…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Here’s how a first-time investor could start buying shares with £3k

Is it possible to start buying shares with £3K? Yes it is -- and here our writer goes into some…

Read more »